Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The primary objective of the study is to determine whether a test titration regimen of ACTIQ treatment will reduce the number of inadequately managed episodes of breakthrough pain for an individual patient by attaining a successful dose of ACTIQ treatment more quickly. The successful ACTIQ dose provides a satisfactory combination of efficacy and tolerability after a single administration, as assessed by the patient.
A Randomised, Open-label, Parallel-group Study to Evaluate the Efficacy and Safety of ACTIQ (Oral Transmucosal Fentanyl Citrate) Titrated According to 2 Regimens in Patients With Cancer and Breakthrough Pain
Study Start Date
Primary Completion Date
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria: Patients are included in the study if all of the following criteria are met:
the patient is at least 18 years old
women must be surgically sterile, 2 years postmenopausal, or if of child-bearing potential, must use a medically accepted method of birth control (ie, barrier method with spermicide, steroidal contraceptive [oral, implanted, and Depo-Provera contraceptives must be used in conjunction with a barrier method], or intrauterine device)
the patient experiences persistent pain associated with cancer or cancer treatment
for at least 7 days before enrolment, the patient has taken either the equivalent of 60 to 1000 mg/day of oral morphine around-the-clock (ATC) or 25 to 300 micrograms/hr of transdermal fentanyl to treat persistent pain
the patient regularly experiences between 1 and 4 episodes of cancer-related BTP per day while taking ATC opioid therapy
the patient experiences at least partial relief of cancer related BTP by administering conventional opioid BTP medication at a dose approximately in the range of one-fifth to one-sixth the 24-hour sustained release dose
the patient is capable of self-administering ACTIQ by sucking lozenge, producing sufficient saliva to dissolve the lozenge over 15 minutes, and swallowing the saliva
a responsible adult caregiver is available to assist the patient in case of emergency if the patient will be taking ACTIQ at home
the patient willingly provides informed consent to participate in this study
Exclusion Criteria: Patients are excluded from participating in this study if 1 or more of the following criteria are met:
the patient experiences uncontrolled or rapidly escalating pain, as determined by the investigator, such that ATC administration of pain medication might be expected to change between the first and last administrations of ACTIQ.
the patient has known or suspected hypersensitivities and/or allergies to fentanyl
the patient has a recent history or current evidence or abuse of alcohol or any other drug substance, licit or collection
the patient has neurological or psychiatric disease sufficient, in the investigator's opinion, to compromise data collection
the patient received strontium-89 therapy within 6o days prior to entering the study
the patient received any other therapy (eg, radiotherapy) within a 1 week period prior to entering the study that, in the investigator's opinion, could alter pain or response to pain medication
the patient has moderate to severe oral mucositis
the patient is pregnant, nursing, or is of child-bearing potential or not taking adequate contraceptive measures
the patient has previously been treated with ACTIQ
the patient has participated in a trial of an unapproved drug in the previous 8 weeks
the patient has been diagnosed with either severe respiratory depression or severe obstructive lung conditions
the patient has used monoamine-oxidase inhibitors (MAOI's) within the 2-week period prior to entering the study